This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.08.008v1 50/19/1813    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sen-Chowdhry, S. Articles by McKenna, W. J. Search for Related Content PubMed Articles by Sen-Chowdhry, S. Articles by McKenna, W. J.

CARDIOVASCULAR GENOMIC MEDICINE

Role of Genetic Analysis in the Management of Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

Cardiology in the Young, The Heart Hospital, University College London, London, United Kingdom

Manuscript received May 3, 2007; revised manuscript received July 2, 2007, accepted August 6, 2007.

^_* Reprint requests and correspondence: Dr. William J. McKenna, Cardiology in the Young, The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, United Kingdom. (Email: william.mckenna{at}uclh.nhs.uk).

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a recognized cause of sudden cardiac death, which may be prevented by timely detection and intervention. Clinical diagnosis of ARVC is fraught with difficulties in both index cases and relatives owing to the nonspecific nature of associated features, diverse phenotypic manifestations, and a lack of conspicuous abnormalities in the early, "concealed" phase. During the past 7 years, researchers have isolated causative mutations in several components of the desmosome, shedding light on the molecular mechanisms underlying the disease and offering the promise of genetic testing as a diagnostic tool. Sequence analysis is likely to be the mainstay of genotyping in ARVC because of marked allelic heterogeneity, frequent "private" mutations, and digenicity in a minority, highlighting the importance of comprehensive genetic screening. The main technical obstacle to implementation of genotyping in clinical practice will be the prohibitive costs of performing sequence analysis of a genomic region exceeding 40 kb. Nevertheless, the success rate of genotyping in ARVC is of the order of 40%, and key clinical applications include confirmatory testing of index cases to facilitate interpretation of borderline investigations and cascade screening of families. The latter is particularly attractive in ARVC, because age-related penetrance otherwise demands lifelong clinical reassessment of extended families. A role for genetic analysis in prognostication is more tenuous at present, but increasing identification of individuals with early and familial disease underscores the need for a definitive risk stratification algorithm in this population.

Abbreviations and Acronyms   ARVD/C = arrhythmogenic right ventricular dysplasia/ cardiomyopathy   ICD = implantable cardioverter-defibrillator   PKP = plakophilin   TGF = transforming growth factor

This article has been cited by other articles:

				A. D. den Haan, B. Y. Tan, M. N. Zikusoka, L. I. Llado, R. Jain, A. Daly, C. Tichnell, C. James, N. Amat-Alarcon, T. Abraham, et al. Comprehensive Desmosome Mutation Analysis in North Americans With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Circ Cardiovasc Genet, October 1, 2009; 2(5): 428 - 435. [Abstract] [Full Text] [PDF]

				Z. A. Bhuiyan, J. D.H. Jongbloed, J. van der Smagt, P. M. Lombardi, A. C.P. Wiesfeld, M. Nelen, M. Schouten, R. Jongbloed, M. G.P.J. Cox, M. van Wolferen, et al. Desmoglein-2 and Desmocollin-2 Mutations in Dutch Arrhythmogenic Right Ventricular Dysplasia/Cardiomypathy Patients: Results From a Multicenter Study Circ Cardiovasc Genet, October 1, 2009; 2(5): 418 - 427. [Abstract] [Full Text] [PDF]

				A. D. Krahn, J. S. Healey, V. Chauhan, D. H. Birnie, C. S. Simpson, J. Champagne, M. Gardner, S. Sanatani, D. V. Exner, G. J. Klein, et al. Systematic Assessment of Patients With Unexplained Cardiac Arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) Circulation, July 28, 2009; 120(4): 278 - 285. [Abstract] [Full Text] [PDF]

				R. E. Hershberger, J. Cowan, A. Morales, and J. D. Siegfried Progress With Genetic Cardiomyopathies: Screening, Counseling, and Testing in Dilated, Hypertrophic, and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Circ Heart Fail, May 1, 2009; 2(3): 253 - 261. [Abstract] [Full Text] [PDF]

				A. Asimaki, H. Tandri, H. Huang, M. K. Halushka, S. Gautam, C. Basso, G. Thiene, A. Tsatsopoulou, N. Protonotarios, W. J. McKenna, et al. A New Diagnostic Test for Arrhythmogenic Right Ventricular Cardiomyopathy N. Engl. J. Med., March 12, 2009; 360(11): 1075 - 1084. [Abstract] [Full Text] [PDF]

				S. G. Priori, C. Napolitano, S. E. Humphries, and J. Skipworth CHAPTER 9 Genetics of Cardiovascular Diseases ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				S. Sen-Chowdhry, P. Syrris, S. K. Prasad, S. E. Hughes, R. Merrifield, D. Ward, D. J. Pennell, and W. J. McKenna Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2175 - 2187. [Abstract] [Full Text] [PDF]